Ab­b­Vie sees a megablock­buster in Vray­lar. Could a new de­pres­sion in­di­ca­tion push peak sales past $4B?

De­spite a bumpy take­off, Ab­b­Vie has some big plans for Vray­lar, the block­buster schiz­o­phre­nia and bipo­lar drug it snapped up from Al­ler­gan a cou­ple of years ago. Look­ing ahead, CEO Richard Gon­za­lez says a sup­ple­men­tal ap­proval in ma­jor de­pres­sive dis­or­der could send sales in­to the stratos­phere — that is, if the FDA is will­ing to get on board.

As promised in the re­cent Q4 call, Ab­b­Vie has sub­mit­ted its sN­DA fil­ing for Vray­lar as an add-on ther­a­py for MDD, one of the most com­mon men­tal dis­or­ders in the US. The com­pa­ny’s hop­ing for a reg­u­la­to­ry de­ci­sion by the end of the year — and if all goes well, Gon­za­lez says the in­di­ca­tion could push peak sales past the $4 bil­lion mark.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER